Transition Therapeutics Inc.


It is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets.
The Company's lead CNS drug candidate is ELND005 for the treatment of agitation or aggression associated with Alzheimer's disease and Down syndrome. Transition's lead metabolic drug candidate is TT401 for the treatment of type 2 diabetes and accompanying obesity. Their main aims are CNS (Central Nervous System) disorders and Metabolic diseases.
Business Type: Nanotextile » | Biotechnology » | Electrotechnics » |
Transition Therapeutics Inc.101 College Street, Suite 220 |
Share with friends:
Next companies in category
Nanotechnology in medicine | Nano materials | Nanotechnology electronics | Nano asociation |
Follow Nanotechnology Journal on
© 2008 - 2022 Nanotechnology research | All rights reserved | Developed by Makovic.net